Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | ADCY1 | Q08828 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12506948 | 0.76 | CDC7 (0.51) | SMN1; SMN2MAPTNPC1RAB9APIM1 | |
| SCHEMBL2188384 | 0.75 | CDK2 (0.52) | SMN1; SMN2MAPTKDM4EADCY1KMT2A | |
| SCHEMBL12507100 | 0.74 | PIM1 (0.48) | SMN1; SMN2MAPTKDM4EADCY1HPGD | |
| SCHEMBL2189787 | 0.74 | KDM4E (0.51) | SMN1; SMN2MAPTKDM4EADCY1KMT2A | |
| SCHEMBL111126 | 0.72 | PGR (0.63) | KDM4EHPGDALDH1A1TP53GAA | |
| SCHEMBL18584869 | 0.71 | CASR (0.43) | PFKFB3PLK1MAPK1ROCK2ROCK1 | |
| SCHEMBL18609246 | 0.70 | CASR (0.40) | MAPTPFKFB3PLK1MAPK1ROCK2 | |
| SCHEMBL12507123 | 0.70 | ROCK2 (0.42) | SMN1; SMN2MAPTPFKFB3PIM1PIM3 | |
| SCHEMBL12507240 | 0.70 | RPS6KB1 (0.44) | SMN1; SMN2MAPTKDM4EHPGDKMT2A | |
| SCHEMBL1961463 | 0.67 | MAPT (0.40) | SMN1; SMN2MAPTKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102197-B1 | 5-([1,3,4]OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4]THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2102197-B1 | 5-([1,3,4]OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4]THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2011-07-13 | — | — | EP | disclosed |
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| EP-2102197-A1 | 5-([1,3,4]OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4]THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008086854-A1 | 5-([1,3,4] OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4] THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008086854-A1 | 5-([1,3,4] OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4] THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | SGK2, SGK1, SGK3 | SMN1; SMN2 4581/4885MAPT 4540/4885KDM4E 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.